8
Total Mentions
8
Documents
58
Connected Entities
Organization referenced in documents
EFTA00282981
th different assay methods or kits cannot be interchangeably. ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics). Not Estab. ng/mL to moderate or marked of the obtained used I 0.33 ¶01/27/2016 % FREE PSA TNP FREE PSA RISK ASSESSMENT The probability of prostate
EFTA00314038
7 g/dL 13.0 17.7 42.2 37.5 51.0 86 fL 79 97 30.0 pg 26.6 33.0 34.8 g/dL 31.5 35.7 14.6 12.3 15.4 242 x10133/uL 150 - 379 50 Not Estab. 37 Not Estab. 5 Not Estab. 7 Not Estab. 1 Not Estab. 2.8 x1083/uL 1.4 - 7.0 2.1 x1023/uL 0.7 - 3.1 0.3 x1083/ul. 0.1 - 0.9 0.4 x1
EFTA00314053
MCHC 34.8 g/dL 31.5 - 35.7 01 RDW 14 .6 12.3 - 15.4 01 Platelets 242 x10E3/uL 150 - 379 01 Neutrophils 50 Not &stab. 01 Lymphs 37 Not Estab. 01 Monocytes 5 Not Estab. 01 EOS 7 Not Estab. 01 8a808 1 Not Estab. 01 Neutrophils (Absolute) 2.8 x10E3/uL 1.4 - 7.0 01 Lymphe (A
EFTA00299784
.8 g/dL 31.5 - 35.7 01 RDW 14.6 t 12.3 - 15.4 01 Platelets 242 x1083/uL 150 - 379 01 Neutrophils 50 I Not Estab. 01 Lymphs 37 % Not Estab. 01 Monocytes 5 * Not Estab. 01 Eos 7 * Not Estab. 01 Basos 1 * Not Estab. 01 Neutrophils (Absolute) 2.8 x10E3/uL 1.4 - 7.0 01
EFTA00299800
51.0 01 86 IL 79 - 97 01 30.0 pg 26.6 - 33.0 01 34.8 g/dL 31.5 - 35.7 01 14.6 t 12.3 - 15.4 01 242 xl0E3/u1 150 - 379 01 50 * Not Estab. 01 37 * Not Estab. 01 5 t Not Estab. 01 7 t Not Estab. 01 1 t Not Estab. 01 2.8 x10E3/uL 1.4 - 7.0 01 Lymphs (Absolute) 2.1
EFTA00599643
the presence or absence of malignant disease. ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics) PSA, FREE 0.33 Not Estab. ng/mL I 0.31 10/27/201S BioReference Laboratories, Inc. Elmwood Park, NJ 07407 James Weisberger M.D. Page 3 of S Laboratory Director Prin
EFTA00582641
th different assay methods or kits cannot be interchangeably. ASSAY INFORMATION: Method Electrocheedluninescence Immunoassay (Roche Diagnostics). Not Estab. ng/mi. to moderate or marked of the obtained used 1 0.33 101/27/2016 % FREE PSA TNP FREE PSA RISK ASSESSMENT The probability of prostate
EFTA01733939
f the presence or absence of malignant disease. ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics) PSA, FREE TNP Not Estab. ng/mL Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis. 0.70 101/27/2016 NOTE: Results cannot be interpre

Jeffrey Epstein
PersonAmerican sex offender and financier (1953–2019)

NEW YORK NY
LocationState of the United States of America

Roche
OrganizationPharmaceutical company

North America
LocationContinent
FREE T4
OrganizationOrganization referenced in documents
BioReference
OrganizationOrganization referenced in documents
PSA Total
OrganizationOrganization referenced in documents
DBili
OrganizationOrganization referenced in documents
TBili
OrganizationOrganization referenced in documents
Roche Diagnostics
OrganizationOrganization referenced in documents
Cholestero
PersonName reference in documents
Leukocyte Esterase
PersonName reference in documents
TOT.,S.
LocationLocation referenced in documents
Epithelial Cells
OrganizationOrganization referenced in documents
Thyroxine
OrganizationOrganization referenced in documents
Lipoprotein
PersonName reference in documents
Elmwood Park
LocationLocation referenced in documents
National Medical Lab
OrganizationOrganization referenced in documents
Alk Phos
OrganizationOrganization referenced in documents
LYMPHS
OrganizationOrganization referenced in documents